Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2007.Podcast to be Available Following Conference Call CAMBRIDGE, Mass. -- Alkermes, Inc. (Nasdaq: ALKS ALKS Alkermes, Inc. (stock symbol) ) will host a conference call at 4:30 p.m. EST on Wednesday, February 7, 2007 to discuss the Company's financial results for its third quarter of fiscal 2007. Management will review the quarter and provide an update on the Company. The conference call will be webcast on the investor relations Investor relations The process by which the corporation communicates with its investors. section of Alkermes' website at www.alkermes.com or may be accessed by dialing 1-866-256-3815 for domestic callers and 1-703-639-1212 for international callers. The conference call ID number is 1031642. A replay of the conference call will be available from 7:30 p.m. EST on Wednesday, February 7, 2007 through 5:00 p.m. EST on Monday, February 12, 2007, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 1031642. Alkermes is also providing a podcast MP3 file available for download on the Alkermes website, which will be available shortly following the conference call and will be available until Thursday, February 15, 2007. Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: the first and only long-acting atypical antipsychotic The atypical anti-psychotics (also known as second generation anti-psychotics) are a class of prescription medications used to treat psychiatric conditions. Some atypical anti-psychotics are FDA approved for use in the treatment of schizophrenia. medication approved for use in schizophrenia marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson; and VIVITROL([R]) (naltrexone naltrexone /nal·trex·one/ (nal-trek´son) an opioid antagonist used as the hydrochloride salt in treatment of opioid or alcohol abuse. nal·trex·one n. An endorphin and narcotic antagonist. for extended-release injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. suspension), the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon Ceph´a`lon n. 1. (Zool.) The head. , Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of widespread, chronic diseases such as central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency , addiction and diabetes. Alkermes' headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion